|Bid||14.550 x 400000|
|Ask||14.635 x 400000|
|Day's Range||14.250 - 14.805|
|52 Week Range||6.684 - 22.700|
|PE Ratio (TTM)||75.05|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||17.58|
VIENNA, Austria and HAMBURG, Germany, Jan. 08, 2018-- APEIRON Biologics AG, a company focused on cancer immunotherapy, and Evotec AG announced today that the companies received the first milestone payment ...
Evotec AG and APEIRON Biologics AG, a company focused on cancer immunotherapy, announced today that the companies received the first milestone payment from Sanofi under a 3-party alliance signed in August 2015.
Evotec AG announced today that its management will be presenting at the 17th German Corporate Conference 2018 jointly hosted by UniCredit and Kepler Cheuvreux, Frankfurt, Germany, and will be attending the 36th Annual J.P.
Evotec AG / Key word : Miscellaneous EVOTEC'S ACADEMIC BRIDGE LAB282 WITH OXFORD UNIVERSITY CELEBRATING ONE YEAR OF IMPACT
Evotec AG / Key word : Miscellaneous EVOTEC RECEIVES CLINICAL MILESTONE AS PART OF ITS DISCOVERY ALLIANCE WITH BOEHRINGER INGELHEIM
Evotec AG announced today that its management will be presenting at the Jefferies 2017 London Healthcare Conference in London, UK, at the German Equity Forum in Frankfurt, Germany, and at the Annual Berenberg European Conference in Surrey, UK, and will be attending DZ BANK Equity Conference in Frankfurt, Germany, and dbAccess Pharmaceutical and Healthcare Corporate Day in London, UK.
Evotec AG announced today that its strategic alliance with Celgene has reached a first milestone triggering revenues of $ 5.0 m to Evotec, which are recognised in the third quarter of 2017.
Evotec AG and Exscientia Ltd today announced that Evotec has made a EUR 15 m investment to take a minority stake in Exscientia.
Evotec AG and MaRS Innovation today announced the launch of "LAB150". This transformational Toronto-based partnership will give Canadian academic institutions and teaching hospitals access to the world-class infrastructure and drug discovery expertise of Evotec and pair it with cutting-edge drug discovery projects emerging from the 15 member institutions of MaRS Innovation.
Evotec AG and the European Investment Bank announced today that the EIB has granted Evotec an unsecured loan facility of up to EUR 75 m to support Evotec's Innovate strategy.
Evotec AG and ABIVAX today announced a strategic collaboration to discover and develop novel treatments for multiple serious viral infectious diseases.
Evotec AG announced today that its management will be presenting at the Morgan Stanley 15th Annual Global Healthcare Conference in New York, USA; 6th German Corporate Conference, Berenberg/Goldman Sachs in Munich, Germany, and Baader Investment Conference, Munich, Germany, and will be attending Goldman Sachs' 7th Annual Biotech Symposium in London, UK, and Bank of America Merrill Lynch Global Healthcare ...
Evotec AG today announced that, effective mid-August 2017, it has successfully completed the acquisition of Aptuit as announced in detail on 30 July 2017.
Evotec AG today announced a strategic collaboration on induced pluripotent stem cell technology with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME, ScreeningPort , Hamburg, as an important element of the existing Evotec/Fraunhofer cooperation agreement signed in 2014.
Evotec AG and Aptuit announced today that they have entered into a definitive agreement under which Evotec will acquire Aptuit for $ 300 m.
Evotec AG today announced that it has entered into a definitive agreement with Aptuit Holdings LLC under which Evotec will acquire all operational business of Aptuit for $ 300 m (approx.
Evotec AG announced today an integrated drug discovery collaboration with STORM Therapeutics to develop new small molecule epigenetic drugs for oncology and other therapeutic areas.
Evotec AG announced today that its multi-target endometriosis alliance with Bayer has advanced a programme from the alliance portfolio into Phase I clinical development for the treatment of endometriosis, triggering a milestone payment to Evotec.
Evotec AG announced today that the Company has been awarded a 'Programm für Innovation' grant for a period of two years from the Hamburgische Investitions- und Förderbank , the central development institution of the Free and Hanseatic city of Hamburg, to identify and develop therapeutic antibodies directed against novel immune-checkpoints on T-cells to improve future cancer treatments.
Evotec AG today announced a collaboration with Censo Biotechnologies Ltd. to source and provide patient-derived induced pluripotent stem cells to support Evotec's broad iPSC platform.
Evotec AG announced today that LAB282, the drug discovery BRIDGE between Oxford University, has made its second round of awards to support promising life sciences ideas emerging from the University.
Evotec AG announced today that it will make a strategic investment as part of Facio Therapies' 2017 funding round together with Australian, European and North American members of the Facioscapulohumeral dystrophy community .